Compare Medpace Holdings Inc (MEDP) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Vipshop Holdings Ltd - ADR trades at $15.06 (market cap $7.20B). The key difference: Medpace Holdings Inc is far larger — about 2.3× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | VIPS | |
|---|---|---|
Market Cap | $16.90B | $7.20B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $20.68 |
52-Week Low | $393.42 | $12.92 |
Enterprise Value | $16.52B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Vipshop (VIPS) trades at $14.49, down 5.97% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The stock shows attractive valuation metrics, including a P/E of 6.79 and P/S of 0.48, alongside strong profitability with an 18.43% ROE. Recent earnings have been mixed, with Q1 2026 EPS meeting expectations, while the company pursues growth through an outlet strategy and REIT spin-off.
The outlook remains positive due to low valuations and profitability, but risks include revenue stagnation and competitive pressures. Analyst consensus is bullish with 53.57% buy ratings, supporting potential upside if earnings growth resumes in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
